Does Rifaximin Chemoprophylaxis Prevent Campylobacteriosis in the Human Challenge Model?

Clayton D. Harro, Joanna E. Rimmer, David Sack, Kawsar R. Talaat, Ramiro L. Gutierrez, Barbara Denearing, Chad K. Porter, Jessica Brubaker, Alexander C. Maue, Renee M. Laird, Frederic Poly, Patricia Guerry (+4 others)
2015 Open Forum Infectious Diseases  
This study showed no significant difference in the development of the primary endpoint, Campylobacteriosis, between subjects treated with rifaximin or placebo. However, the difference in mean total loose stool output (mL) is significantly reduced in the rifaximin group, and within this group a reduction in the maximum volume of loose stools in 24 hours was also observed. Therefore, whilst rifaximin does not protect against Campylobacteriosis, this objective data relating to stool volume
more » ... tool volume suggests that fluid loss is reduced, and therefore should be considered when evaluating the efficacy of rifaximin in reducing the severity of the burden of disease in all cause bacterial travelers' diarrhea. Based on the high diarrhea attack rates noted in this human challenge model, the efficacy of rifaximin chemoprophylaxis against campylobacteriosis in a field setting requires further evaluation.
doi:10.1093/ofid/ofv133.613 fatcat:yu35xtexpvdshay5je6v4qvqt4